Does Takeda Offer Value After Latest FDA Approval and Share Price Dip in 2025? [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
The company's been on a bit of a roller coaster lately, but not in a way that should scare off patient investors. In the short term, Takeda's share price has dipped a little, down 0.7% over the past week and 5.8% in the last month. Still, if you zoom out, the story looks much more encouraging, with a 0.7% gain for the year to date, a solid 2.5% return over the past twelve months, and even stronger returns of 28.3% and 50.1% over three and five years, respectively. These numbers suggest that Takeda's longer-term growth potential is winning out over any current doubts about the pharmaceutical sector or broader market volatility. As we dig into the numbers, it is clear the stock is not flashing every classic sign of being undervalued, but it does check a couple of boxes, scoring 2 out of 6 on our valuation screen. So, how should you interpret these mixed valuation signals, and what do they mean for your decision-making process? Let us break down the main valuation methods to see what i
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- American Neurology Summit 2025 Achieves Major Success With Full Attendance and High EngagementPR Web
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 12/5/25 - Form 144
- 12/4/25 - Form 144
- 11/28/25 - Form 6-K
- TAK's page on the SEC website